Single-dose anthrax vaccine shows promise in testing phase

A non-human primate study by the National Institutes of Health (NIH) using an anthrax vaccine from Immunovaccine, Inc., found significant immunity to anthrax after only a single dose, the company reported today.

Researcher's from the NIH's National Institute of Allergy and Infectious Diseases (NIAID) vaccinated six monkeys with Immunovaccine's DepoVax vaccine. All developed immunity to the anthrax infection.

Five monkeys in a control group were given two doses of BioThrax, which is currently the only Food and Drug Administration approved vaccine for anthrax. Four of the monkeys were found to have developed immunity. 

“We previously announced data that demonstrated single-dose protection in rabbits and the potential for single dose protection in non-human primates," Marc Mansour, the CEO of Immunovaccine, said. "Now we report for the first time the protective capability of a single dose of a DepoVax-based anthrax vaccine in non-human primates. The results... demonstrate the consistent performance of DepoVax in producing protective immunity with a single dose, which may translate to other infectious disease applications including Ebola."

More studies will be conducted on DepoVax to determine the potential of its effectiveness as a single-dose protection against anthrax.

Organizations in this Story

Immunovaccine National Institutes of Health

Want to get notified whenever we write about any of these organizations ?
Next time we write about any of these organizations, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.